Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Year 2022, Volume: 5 Issue: 2, 698 - 701, 15.03.2022

Emel Atayık , Gökhan Aytekin

https://doi.org/10.32322/jhsm.1026619

Abstract

Coronavirus disease 2019 (COVID-19) is the general term used for pneumonia caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Keeping the infected individuals in quarantine is very effective in preventing the spread of the disease but isolation and quarantine period increase the risk of household transmission. By December 2020, the rate of household transmission of SARS-CoV-2 has reached up to 85%. Both omalizumab and mepolizumab are used for the treatment of severe persistent asthma. In addition, omalizumab also has an indication for use in chronic urticaria. Both medications have been shown to have some antiviral effects. So, we aimed to discuss potential protective effects of these agents against household transmission of SARS-CoV-2 by reporting six different patients who remained uninfected despite PCR (Polymerase Chain Reaction) (+) SARS-CoV-2 individuals at home and were being treated with monoclonal antibodies.

Keywords

omalizumab, mepolizumab, SARS-CoV-2, omalizumab, mepolizumab, SARS-CoV-2

Project Number

2021/020

References

• Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics 2020; 52: 549-57.
• Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis 2020; 98: 180-6.
• Qian M, Jiang J. COVID-19 and social distancing. Z Gesundh Wiss 2020: 1-3.
• Mizumoto K, Chowell G. Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020. Infect Dis Model 2020; 5: 264-70.
• Madewell ZJ, Yang Y, Longini IM Jr., Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open 2020; 3: e2031756.
• Atayık E, Aytekin GJAAI. SARS-CoV-2 in a patient with persistent asthma taking omalizumab: the first case in Turkey. Asthma Allerg Immunol 2020; 18: 23-6.
• Worldometer. COVID-19 Corona virus pandemic 2021, January 7 [Available from: https: //www.worldometers.info/coronavirus/?zarsrc=130.
• Fick RB, Jr. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med 1999; 5: 76-80.
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016; 137: 1742-50 e4.
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 2017; 9: CD010834.
• Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020; 8: 436-8.
• Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146: 110-8.
• Team CC-R. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 422-6.
• Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J 2020; 13: 100126.
• Li G, He X, Zhang L, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun 2020; 112: 102463.
• Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 2018; 141: 1735-43 e9.
• Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol 2019; 143: 923-6 e1.
• Cildag S, Senturk T. The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. Postepy Dermatol Alergol 2018; 35: 516-9.
• Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. Mucosal Immunol 2015; 8: 464-75.
• Sikriwal D, Seth D, Parveen S, Malik A, Broor S, Batra JK. An insertion in loop L7 of human eosinophil-derived neurotoxin is crucial for its antiviral activity. J Cell Biochem 2012; 113: 3104-12.
• Samarasinghe AE, Melo RC, Duan S, et al. Eosinophils promote antiviral immunity in mice infected with influenza A virus. J Immunol 2017; 198: 3214-26.
• Handzel ZT, Busse WW, Sedgwick JB, et al. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol. 1998; 160: 1279-84.
• Oroojalian F, Haghbin A, Baradaran B, et al. Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials. Int J Biol Macromol 2020; 165: 18-43.
• Sabogal Pineros YS, Bal SM, van de Pol MA, et al. Anti-IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL). a placebo-controlled, double-blind study. Am J Respir Crit Care Med 2019; 199: 508-17.